Evidence map›Paper›PMID 29197935›Full record

ReviewHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2018

How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension.

Giuliano Tocci, Giovambattista Desideri, Elisa Roca, Calogero Calcullo, Massimo Crippa, Nicola De Luca, Giovanni Vincenzo Gaudio, Laura Maria Lonati, Leo Orselli, Angelo Scuteri and 4 more

Open access · hybridAbstract readReview
In one paragraph

Review in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Oxidative Regulation of Vascular CaAntioxidants (Basel, Switzerland) · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Giuliano TocciDivision of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy. giuliano.tocci@uniroma1.it.ORCID http://orcid.org/0000-0002-0635-4921
Giovambattista DesideriMeSVA Department, Chair and School of Geriatric Medicine,Civil Hospital of Avezzano, Division of Geriatric Medicine, University of L'Aquila, Coppito, Italy.
Elisa RocaDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Calogero CalculloASL Agrigento, Agrigento, Italy.
Massimo CrippaOspedale di Gardone Val Trompia, Brescia, Italy.
Nicola De LucaHypertension Research Center, Federico II University, Naples, Italy.
Giovanni Vincenzo GaudioOspedale di Somma Lombardo, Varese, Italy.
Laura Maria LonatiUniversità di Milano, Milan, Italy.
Leo OrselliASL Bologna, Bologna, Italy.
Angelo ScuteriDepartment of Medicine, UOC Hypertension and Nephrology, Policlinico Tor Vergata, Rome, Italy.
Vito VulpisDepartment of Neurological and Psychiatric Sciences, Neurophysiopathology, Hypertension, Medical School of Bari, University of Bari, Bari, Italy.
Benedetto AconeIstituto "Cartesio" di Venezia, Venezia, Italy.
Augusto ZaninelliSchool of Medicine, University of Florence, Florence, Italy.
THYPERevolution Steering Committee
Federico II University Hospital · ITIstituto Neurologico Mediterraneo · ITOspedale Civile di Venezia · ITPoliclinico Tor Vergata · ITUniversity of Bari Aldo Moro · ITUniversity of Brescia · ITUniversity of Florence · ITUniversity of L'Aquila · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Essential hypertension is a complex clinical condition, characterized by multiple and concomitant abnormal activation of different regulatory and contra-regulatory pathophysiological mechanisms, leading to sustained increase of blood pressure (BP) levels. Asymptomatic rise of BP may, indeed, promote development and progression of hypertension-related organ damage, which in turn, increases the risk of major cardiovascular and cerebrovascular events. A progressive and independent relationship has been demonstrated between high BP levels and increased cardiovascular risk, even in the high-to-normal range. Conversely, evidence from randomized controlled clinical trials have independently shown that lowering BP to the recommended targets reduces individual cardiovascular risk, thus improving event-free survival and reducing the incidence of hypertension-related cardiovascular events. Despite these benefits, overall rates of BP control remain poor, worldwide. Currently available guidelines support a substantial equivalence amongst various antihypertensive drug classes. However, several studies have also reported clinically relevant differences among antihypertensive drugs, in terms of both BP lowering efficacy and tolerability/safety profile. These differences should be taken into account not only when adopting first-line antihypertensive therapy, but also when titrating or modulating combination therapies, with the aim of achieving effective and sustained BP control. This review will briefly describe evidence supporting the use of dihydropyridinic calcium channel blockers for the clinical management of hypertension, with a particular focus on barnidipine. Indeed, this drug has been demonstrated to be effective, safe and well tolerated in lowering BP levels and in reducing hypertension-related organ damage, thus showing a potential key role for improving the clinical management of hypertension.

Indexed as

Medication AdherenceAntihypertensive AgentsBlood PressureCalcium Channel BlockersDihydropyridinesEssential HypertensionHumansNifedipineRisk FactorsTreatment OutcomeVasodilator Agents1,4-dihydropyridineAntihypertensive AgentsCalcium Channel BlockersDihydropyridinesmepirodipineNifedipineVasodilator AgentsAntihypertensive therapyBarnidipineCombination therapyDihydropyridinic calcium channel blockersHypertensionMonotherapy

Identifiers

PMID29197935
PMCPMC5842506
OpenAlexW2772152986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.